Durata shares jump following positive FDA AdComm meeting

|About: Durata Therapeutics (DRTX)|By:, SA News Editor

Durata Therapeutics (DRTX) soars 9.5% premarket after an FDA advisory panel unanimously recommended approval of the company's Dalvance antibiotic for acute bacterial skin conditions.

"It's a highly effective drug, as demonstrated in the trial," said Thomas Moore, a clinical professor of medicine at the University of Kansas, who was on the panel.

The committee also voted to recommend the authorization of Cubist Pharmaceuticals' Sivextro, another antibiotic for skin problems.